Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q3 2023 Earnings Presentation

16 slides from Abcellera Biologics's earnings presentation, Nov 2, 2023

  1. Slide 1: Q3 2023 Business Update

    Q3 2023 BUSINESS UPDATE NOVEMBER 2, 2023 COPYRIGHT © ABCELLERA

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation contains forward-looking statements, including These statements involve risks, uncertainties and other factors that may statements made pursuant to the safe harbor provisions of the Private cause actual results, levels of activity, performance, or achievements to be Q3 2

  3. Slide 3: Continued focus on high-value programs

    Q 3 2 0 2 3 . B U S I N E S S U P D AT E S U M M A R Y. $813M in total cash, Continued focus cash equivalents, & marketable securities Q3 2023 BUSINESS UPDATE on high-value 182 cumulative programs programs under contract & strategic 110 cumulative partnered programs started partnerships 10 COPYRIGHT

  4. Slide 4: Two AbCellera-led programs advancing into IND-enabling studies

    PROGRAMS Two AbCellera-led programs advancing into IND-enabling studies. Q3 2023 BUSINESS UPDATE MOLECULE TARGET INDICATION THERAPEUTIC POTENTIAL POTENTIAL AREA DIFFERENTIATION MARKET SIZE immunology and ABCL575 OX40L atopic dermatitis inflammation best in class $17B by 2032* undisclosed metabolic a

  5. Slide 5: Strategic collaborations with new and existing partners

    PARTNERSHIPS Strategic collaborations with new and existing partners. Q3 2023 BUSINESS UPDATE 8 programs under contract 4 new 1 program under contract 2 completed Regeneron has exercised its rights to advance antibody candidates into further COPYRIGHT © ABCELLERA MULTIPLE INDICATIONS preclinical dev

  6. Slide 6: Delivering on stated business objectives

    PRIORITIES Delivering on stated business objectives. Q3 2023 BUSINESS UPDATE ELECT EXECUTE ADVANCE candidates for strategic T-cell engager IND-enabling studies partnerships platform COPYRIGHT © ABCELLERA 6

  7. Slide 7: Q3 2023 Financials Update

    Q3 2023 COPYRIGHT © ABCELLERA FINANCIALS UPDATE

  8. Slide 8: Continuing portfolio growth

    FINANCIALS Continuing portfolio growth. Cumulative # of Cumulative # of Partnered Program Starts Molecules in the Clinic Q3 2023 BUSINESS UPDATE 110 10 110 10 100 9 Total # of 90 8 80 7 Programs Under Contract 182 70 6 60 5 50 4 Total # of 40 30 3 Discovery Partners 42 20 2 10 1 0 0 2015 16 17 18 19

  9. Slide 9: Now molecules in the clinic

    FINANCIALS Now 10 molecules in the clinic. MOLECULE STAGE THERAPEUTIC AREA PARTNER PROGRAM TYPE bamlanivimab Marketed, Emergency Use • infectious disease: COVID-19 (LY-CoV555) Authorization (EUA) AbCellera-initiated program FINANCIALS PARTNERED bebtelovimab Marketed, Emergency Use • infectious disea

  10. Slide 10: $7M total revenue, predominantly from discovery activity

    FINANCIALS $7M total revenue, predominantly from discovery activity. Revenue USD $101.4M ROYALTIES Q3 2023 BUSINESS UPDATE MILESTONES LICENSING RESEARCH FEES $6.6M $0.2M $7.5M $6.4M COPYRIGHT © ABCELLERA Q3 2022 Q3 2023 10

  11. Slide 11: Operating expenses reflect ongoing investments, predominantly in R&D

    FINANCIALS Operating expenses reflect ongoing investments, predominantly in R&D. Operating Expenses USD RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN Q3 2023 BUSINESS UPDATE +$11.3M $37.9M $26.6M +$0.6M $13.8M $14.4M +$0.4M COPYRIGHT © ABCELLERA $3.1M $3.5M Q3 2022 Q3 2023 Q3 2022 Q3 2023

  12. Slide 12: Net loss of $29M; ($0.10) per share

    FINANCIALS Net loss of $29M; equivalent to ($0.10) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC EARNINGS PER SHARE: DILUTED Q3 2023 BUSINESS UPDATE $26.6M $0.09 $0.08 -$28.6M -$0.10 -$0.10 COPYRIGHT © ABCELLERA Q3 2022 Q3 2023 Q3 2022 Q3 2023 Q3 2022 Q3 2023 12

  13. Slide 13: Over $800M in total cash, equivalents, and marketable securities

    FINANCIALS Over $800M in total cash, equivalents, and marketable securities. Cash Flows USD $915M $813M Q3 2023 BUSINESS UPDATE $500M Marketable Securities $613M Marketable Securities ($24M) $102M Marketable Securities (net) $387M $95M Cash & Other $7M Equivalents ($197M) $0M $172M Cash & COPYRIGHT

  14. Slide 14: Thank you

    COPYRIGHT © ABCELLERA 14 Q3 2023 BUSINESS UPDATE YOU THANK

  15. Slide 15: Earnings call summary

    EARNINGS CALL SUMMARY EARNINGS CALL SUMMARY Note: This document contains a condensed summary of AbCellera’s 2023-11-02 earnings call. It should be read in conjunction with, and in the context of, the contents of the call itself. AbCellera achieves a • ABCL575 targets the OX40 ligand (OX40L) and has

  16. Slide 16: Earnings call summary

    AbCellera maintains • AbCellera announced a new partnership with Incyte, with one new program under contract for an indication committed to accelerating in oncology. EARNINGS CALL SUMMARY high-value programs from • AbCellera expanded its existing partnership with Regeneron, with four new programs un

AbCellera Biologics — Q3 2023 Earnings Presentation on 6ix